2025 Preliminary Earnings: Net Profit Plunges 58.5% Due to Tax Investigation Losses
-
Revenue KRW 239.5B, up 6.3% YoY; Operating profit KRW 25.5B, up 1.4% YoY, solid core business
-
Pre-tax profit KRW 18.4B, down 27.6%; Net profit KRW 8.8B, down 58.5% YoY
-
Decline due to non-recurring losses from a tax investigation for 2020-2024
-
Total assets KRW 417.8B, liabilities KRW 104.1B, equity KRW 313.7B; no capital impairment
-
Unaudited figures subject to change after external audit
KOSPI Filing Information
-
Filing: Change in Sales or Profit Structure of 30% (15% for Large Corporations) or More
-
Company: Hana Pharm (293480)
-
Submission: Hana Pharm. Co., Ltd.
-
Receipt: 02-03-2026
-
Under KRX KOSPI Market Division